TScan Therapeutics (TCRX) Capital Expenditures (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly Capital Expenditures came in at $70000.0 in Q1 2026, down 95.43% year-on-year from $1.5 million in Q1 2025, and up 255.56% on a QoQ basis from -$45000.0 in Q4 2025.
TScan Therapeutics (TCRX) Capital Expenditures (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of Capital Expenditures data on file, last reported at $70000.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 95.43% year-over-year to $70000.0 in Q1 2026; TTM through Mar 2026 was -$1.5 million, a 131.28% decrease from a year earlier, with the FY2025 full-year figure at $7000.0, down 99.82% from the prior year.
- Capital Expenditures for Q1 2026 stood at $70000.0, up from -$45000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for TCRX reached as high as $1.9 million in Q2 2022 and fell as low as -$1.9 million in Q3 2022.
- Historically, Capital Expenditures has averaged $273352.9 across 5 years, with a median of $70000.0 in 2026.
- Across the five-year window, Capital Expenditures jumped 2837.5% in 2024 and sank 170.07% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at -$128000.0 in 2022, then surged by 67.19% to -$42000.0 in 2023, then soared by 2214.29% to $888000.0 in 2024, then slumped by 105.07% to -$45000.0 in 2025, then surged by 255.56% to $70000.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $70000.0 in Q1 2026, -$45000.0 in Q4 2025, and -$876000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | 70,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2025 | -876,000.00 |
| Sep 30, 2025 | -876,000.00 |
| Jun 30, 2025 | -604,000.00 |
| Jun 30, 2025 | -604,000.00 |
| Mar 31, 2025 | 1.53 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 888,000.00 |
| Dec 31, 2024 | 888,000.00 |
| Sep 30, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 862,000.00 |
| Jun 30, 2024 | 862,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |